BioAdvance News

Melior Pharmaceuticals Enrolls Last Subject in Phase 2b Study with Tolimidone for Type 2 Diabetes

By WebmasterOctober 16, 2018November 1st, 2024No Comments

Melior Pharmaceuticals Enrolls Last Subject in Phase 2b Study with Tolimidone for Type 2 Diabetes
– Last subject randomized in Phase 2b study-

– Study randomized 433 subjects across 61 sites in 2 countries-

Previous PostPalvella Therapeutics to Present Update on PTX-022 at Pachyonychia Congenita Project Patient Support Meeting in London, UK
Next PostRelmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels